Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

Pediatr Infect Dis J. 2024 May 1;43(5):e155-e159. doi: 10.1097/INF.0000000000004271. Epub 2024 Feb 2.

Abstract

We evaluated the effectiveness and safety of direct-acting antivirals in adolescents with hepatitis C (HCV)/HIV coinfection using pooled individual patient-level data from 5 European cohorts. Of 122 participants in follow-up from November 2013 to August 2021, 19 were treated <18 years of age; of 15 with HCV RNA available at/after 12 weeks post-treatment, all had sustained virologic response with acceptable safety. This evidence addresses an important gap in knowledge of treatment outcomes in adolescents with HCV/HIV coinfection in real-life settings.

MeSH terms

  • Adolescent
  • Antiviral Agents* / adverse effects
  • Antiviral Agents* / therapeutic use
  • Child
  • Coinfection* / drug therapy
  • Coinfection* / virology
  • Europe
  • Female
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Hepacivirus / drug effects
  • Hepatitis C* / drug therapy
  • Humans
  • Male
  • Sustained Virologic Response
  • Treatment Outcome

Substances

  • Antiviral Agents